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Abstract 73 
Background 74 
Cannabidiol (CBD) has potential therapeutic benefits for people with psychiatric disorders 75 
characterised by reward function impairment. There is existing evidence that CBD may 76 
influence some aspects of reward processing. However, it is unknown whether CBD acutely 77 
affects brain function underpinning reward anticipation and feedback. 78 
 79 
Hypotheses 80 
We predicted that CBD would augment brain activity associated with reward anticipation and 81 
feedback. 82 
 83 
Methods 84 
We administered a single 600mg oral dose of CBD and matched placebo to 23 healthy 85 
participants in a double-blind, placebo-controlled, repeated-measures design. We employed 86 
the monetary incentive delay (MID) task during functional magnetic resonance imaging 87 
(fMRI) to assay the neural correlates of reward anticipation and feedback. We conducted 88 
whole brain analyses and region-of-interest (ROI) analyses in pre-specified reward-related 89 
brain regions. 90 
 91 
Results 92 
The MID task elicited expected brain activity during reward anticipation and feedback, 93 
including in the insula, caudate, nucleus accumbens, anterior cingulate, and orbitofrontal 94 
cortex. However, across the whole brain, we did not find any evidence that CBD altered 95 
reward-related brain activity. Moreover, our Bayesian analyses showed that activity in our 96 
 5 
ROIs was similar following CBD and placebo. Additionally, our behavioural measures of 97 
motivation for reward did not show a significant difference between CBD and placebo. 98 
 99 
Discussion 100 
CBD did not acutely affect the neural correlates of reward anticipation and feedback in 101 
healthy participants. Future research should explore the effects of CBD on different 102 
components of reward processing, employ different doses and administration regimens, and 103 
test its reward-related effects in people with psychiatric disorders. 104 
  105 
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Introduction 106 
Reward processing refers to the neural, psychological and behavioural processes that underpin 107 
the seeking and consumption of rewards (Berridge et al., 2009). The human brain reward 108 
system is made up of key regions such as the ventral tegmental area (VTA), ventral and dorsal 109 
striatum, anterior cingulate cortex, the orbitofrontal cortex, ventral pallidum, amygdala, insula, 110 
thalamus and parahippocampal regions (Haber and Knutson, 2010; Knutson and Greer, 2008). 111 
Fronto-striatal loops pass reward-related information from the prefrontal cortex to subcortical 112 
regions and back again, such that organisms can orient attention to, be motivated for, and 113 
consume rewards (Haber and Knutson, 2010). 114 
 115 
Reward processing is perturbed in a variety of psychiatric disorders, including depression 116 
(Eshel and Roiser, 2010; Knutson, Wimmer, et al., 2008; Whitton et al., 2015), addiction 117 
(Balodis and Potenza, 2015; Goldstein and Volkow, 2011) and schizophrenia (Gold et al., 118 
2008; Juckel et al., 2006; Strauss et al., 2013). Dysfunctional reward processing therefore 119 
represents an important transdiagnostic neurocognitive mechanism which may contribute to 120 
the emergence of various psychiatric disorders (Husain and Roiser, 2018; Insel, 2010; Whitton 121 
et al., 2015). Hence, the reward circuit is a potential target for novel psychiatric drug treatments. 122 
Successful manipulation of the reward system could lead to the amelioration of impaired 123 
reward learning, motivation and pleasure, observed across various clinical diagnoses. 124 
 125 
The endocannabinoid system plays an important role in modulation of the brain’s reward 126 
processes (Bloomfield et al., 2016; Parsons and Hurd, 2015; Solinas et al., 2009). CB1 127 
receptors are expressed at a moderate level at the origin of the mesolimbic dopamine pathway, 128 
the VTA, and at a higher level at the terminal region, the nucleus accumbens (NAcc) (Curran 129 
et al., 2016; Solinas et al., 2009). 130 
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 131 
Cannabidiol (CBD) is the second most abundant cannabinoid in the cannabis plant (Upton et 132 
al., 2014; Pertwee, 2008) and at typical doses CBD is non-intoxicating (Haney et al., 2016; 133 
Hindocha et al., 2015; Lawn et al., 2016; Martin-Santos et al., 2012). CBD has therapeutic 134 
potential in a variety of psychiatric disorders (Freeman et al., 2019; Khan et al., 2020). 135 
Preclinical research has demonstrated that CBD administration can affect reward-related 136 
behaviours, particularly reducing drug-seeking behaviour (Hay et al., 2018; Katsidoni et al., 137 
2013; Parker et al., 2004; Ren et al., 2009; Schier et al., 2014; Viudez-Martínez et al., 2018). 138 
Speculatively, CBD could ameliorate addictive behaviour by enhancing the sensitivity of the 139 
reward system to natural rewards, such that pharmacological rewards are less desired. The 140 
effects of CBD on the mesolimbic dopamine system are, however, equivocal (Renard et al., 141 
2017). 142 
 143 
Human research has shown that CBD can acutely alter neural, behavioural and psychological 144 
processes relating to reward, including effort sensitivity (Lawn et al., 2016), attentional bias to 145 
drug pictures (Hindocha et al., 2018; Morgan et al., 2010), drug consumption (Freeman et al., 146 
in press; Morgan et al., 2013), neural response to music reward (Freeman et al., 2018) and 147 
levels of stress-induced social anxiety (Bergamaschi et al., 2011; Zuardi et al., 1993), without 148 
producing reinforcing or unpleasant side-effects (Haney et al., 2016). However, it is not known 149 
if CBD specifically acts on the human brain’s reward circuitry, or acts by another mechanism. 150 
Furthermore, if CBD does act on the reward system, its effects on reward anticipation and 151 
reward feedback have not been parsed. 152 
 153 
The monetary incentive delay (MID) task is a well-validated functional magnetic resonance 154 
imaging (fMRI) task which, through its structure, allows for investigation of the neural 155 
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correlates of reward anticipation and reward feedback (Balodis and Potenza, 2015; Knutson et 156 
al., 2001). Meta-analyses of MID task results show reward anticipation and feedback recruit 157 
overlapping and distinct regions (Knutson and Greer, 2008; Oldham et al., 2018). Both 158 
processes activate striatal regions, while reward anticipation activates the thalamus and insula, 159 
and reward feedback preferentially activates prefrontal cortex areas. Importantly, neural 160 
activity during reward anticipation in the ventral striatum correlates with dopamine release in 161 
the same region (Schott et al., 2008), demonstrating the task engages the mesolimbic dopamine 162 
system. 163 
 164 
CBD seemingly has opposite effects to the primary intoxicating cannabinoid found in cannabis, 165 
delta-9-tetrahydracannabinol (THC), on both brain and behavioural outcomes (Bhattacharyya 166 
et al., 2010; Bloomfield et al., 2016; Englund et al., 2013). CBD enhanced striatal activation 167 
during a verbal memory task, while THC dampened striatal activity (Bhattacharyya et al., 168 
2010). In the MID task, acute THC administration has been shown to attenuate the widespread 169 
neural response to reward feedback (van Hell et al., 2012) and attenuate the neural response in 170 
the nucleus accumbens during reward anticipation in people with nicotine dependence (Jansma 171 
et al., 2013). Therefore, one might expect CBD to do the opposite: augment neural response to 172 
reward anticipation and feedback. Furthermore, a pro-reward function action could underlie 173 
CBD’s putative anti-addiction, anti-depressant and anxiolytic effects. 174 
 175 
In summary, the endocannabinoid system plays an important role in the brain’s reward circuitry 176 
and both preclinical and human research has demonstrated that CBD can modulate reward-177 
related behaviours. However, previous human studies have tended to investigate CBD’s impact 178 
alongside THC. Moreover, they have focused on psychiatric symptom-based measures, rather 179 
than precise components of reward processing, such as anticipatory and consummatory reward 180 
 9 
processes which are indexed by the well-validated MID task. No study has examined the 181 
specific, isolated effect of CBD on the human brain during reward processing. Based on its 182 
opposing effects to THC and its ostensibly therapeutic effects in disorders characterised by 183 
reward dysfunction, we predicted that CBD would augment the neural response to reward 184 
anticipation and feedback. 185 
  186 
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Methods 187 
Design and participants 188 
The study used a double-blind, randomized, placebo-controlled, repeated-measures design to 189 
compare the effects of oral CBD 600mg with matched placebo (PBO). Drug order was balanced 190 
and randomised. Drug order was completely concealed from participants and concealed from 191 
experimenters until data collection, entry, and analysis had been completed. 192 
 193 
We tested 28 healthy participants. Four participants did not complete both sessions, so they 194 
were excluded. Furthermore, one participant did not complete the MID task correctly, so they 195 
were excluded. That left 23 participants in our analysis. 196 
 197 
Participants were recruited through public advertisement. Inclusion criteria were: (1) age 18-198 
70 years; (2) right-handed; (3) fluent in English. Exclusion criteria were: (1) positive urine 199 
screen for recreational drug use (Alere Toxicology UC-10A; amphetamines, barbiturates, 200 
benzodiazepines, cocaine, methamphetamine, morphine, methadone, phencyclidine, tricyclic 201 
antidepressants, THC), (2) recent (within the past six months) use of any psychotropic 202 
(recreational or medical) drug, including cannabis, (3) positive breath test for alcohol, (4) 203 
carbon monoxide ≥ 5 parts per million (ppm), (5) problematic alcohol use, as defined by a score 204 
≥ 8 on the Alcohol Use Disorder Identification Test (AUDIT) (Saunders et al., 1993), (6) more 205 
than ten lifetime uses of cannabis or CBD, (7) more than five lifetime uses of any other 206 
recreational drug, (8) nicotine dependent, as defined by a score greater than three on 207 
Fagerstrom Test for Nicotine Dependence (Heatherton et al., 1991), (9) current or past mental 208 
or physical health issues or learning impairments, based on an adapted version of the 209 
Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) Structured Clinical 210 
Interview (SCID) (Gibbon and Spitzer, 1997), (10) positive reading on urine pregnancy test, 211 
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(11) breast-feeding, (12) known allergies or aversions to CBD, microcrystalline cellulose, 212 
gelatine or lactose, (13) colour blindness, (14) MRI contraindications, (15) current use of 213 
psychiatric medications. 214 
 215 
Participants were reimbursed £10/hour for their time. This study was approved by the UCL 216 
ethics committee (Project Number: 3325/002), and all participants provided written informed 217 
consent.  218 
 219 
Assessments 220 
The Monetary Incentive Delay (MID) task (Knutson et al., 2000) (Figure 1) 221 
The MID task is a well-validated task that allows measurement of neural activity during reward 222 
anticipation and reward feedback using functional magnetic resonance imaging (fMRI). We 223 
used an adapted version of the original (Knutson et al., 2000). 224 
 225 
In our version of the task, a cue (a square) is first presented for 500ms, which signals whether 226 
the trial is a win trial (if the square is orange) or a neutral trial (if the square is blue). On a win 227 
trial, the participant has the opportunity to win 30p if they respond to a subsequent target in 228 
time. On a neutral trial, the participant cannot win or lose any money, but they are asked to 229 
respond to the subsequent target as quickly as they can anyway. Following the cue, there is a 230 
blank screen, the anticipation phase, for 2-4s in which the participant waits for the target. 231 
Subsequently, the target (a white square) is presented and the participant must respond to it as 232 
quickly as they can by pressing a button with their thumb on their right hand. Initially, 233 
participants must respond to the target within 300ms in order to get a ‘hit’. However, following 234 
a successful ‘hit’, the next trial’s target must be responded to within a time that is 16.67ms 235 
shorter than the previous trial in order to get another ‘hit’. Following a ‘miss’, the next trial’s 236 
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target must be responded to within a time that is 16.67ms longer than the previous trial in order 237 
to get a ‘hit’. This is to calibrate the participant’s performance to ‘hit’ roughly 50% of the time. 238 
Following the target, feedback is presented for roughly 1000ms (although this changes on a 239 
trial-by-trail basis along with changes in target duration). If it is a ‘win’ trial and the participant 240 
gets a ‘hit’, then the participant wins 30p and is told ‘Hit. You win 30p’. If it is a ‘win’ trial 241 
and the participant gets a ‘miss’, then the participant does not win money and is told ‘Miss’. If 242 
it is a ‘neutral’ trial and the participant gets a ‘hit’, then the participant does not win money and 243 
is told ‘Hit’. If it is a ‘neutral’ trial and the participant gets a ‘miss’, then the participant does 244 
not win money and is told ‘Miss’. The current total won is always displayed on the feedback 245 
screen. Following the feedback, there is an inter-trial interval (ITI) between 1.2 and 9.2s when 246 
a blank screen is shown.  247 
 248 
There are 48 trials in total, of which 24 are neutral trials in which no money can be earned and 249 
24 are win trials in which money can be earned. The order of win trials was fixed, so that win 250 
trials did not appear consecutively. Each win trial provides the opportunity to win 30p; this 251 
amount does not vary, as in some previous MID task versions (Knutson et al., 2008). There are 252 
also no loss trials. The task lasts for 12 minutes. 253 
 254 
The MID task produces measures of brain activity associated with reward anticipation and 255 
reward feedback. It also produces behavioural measures of mean reaction time to respond to 256 
the target on successful ‘win’ and ‘neutral’ trials and the proportion of ‘hits’ on ‘win’ and 257 
‘neutral’ trials. 258 
 259 
[Insert Figure 1] 260 
 261 
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Demographics 262 
We recorded participants’ age, sex, weight and BMI. 263 
 264 
Beck Depression Inventory (BDI) (Beck et al. 1996) 265 
A self-reported scale of depression severity which consists of 21 items. This measured the 266 
participants’ depressive symptomatology over the preceding two weeks to the first study visit. 267 
Higher scores reflect a higher severity of depression. 268 
 269 
Alcohol Use Disorder Identification Test (AUDIT) (Saunders et al., 1993) 270 
A self-reported scale which screens for problematic alcohol use and consists of 10 items. Scores 271 
range from 0 to 40, with higher scores reflecting more severe problematic alcohol use. A score 272 
of 8 or more is considered hazardous. 273 
 274 
Fagerstrom Test for Nicotine Dependence (FTND) (Heatherton et al., 1991)  275 
A self-reported scale of nicotine dependence consisting of six items. Total scores range from 0 276 
to 10, with higher scores reflecting higher nicotine dependence. 277 
 278 
Wechsler Test for Adult Reading (WTAR) (Ginsberg et al., 2003) 279 
A test of reading ability which is a proxy of verbal intelligence. It includes 50 words that must 280 
be read aloud and pronounced correctly. 281 
 282 
Plasma CBD levels 283 
Blood samples were collected using EDTA vacutainers and centrifuged immediately. Plasma 284 
samples were stored at -80oC prior to analysis. CBD concentrations were determined using gas 285 
chromatography mass spectroscopy (GC/MS) with a lower limit of quantification of 0.5mg/ml. 286 
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Drug Administration 288 
Participants were administered a single dose of 600mg oral CBD (pure synthetic (-)-CBD, STI 289 
Pharmaceuticals, Essex, England) or matched placebo (lactose powder) in identical, opaque 290 
capsules on each testing session. The CBD was formulated in 50mg capsules. Participants 291 
swallowed all 12 capsules at their own pace under invigilation of the experimenter. 600mg was 292 
chosen as it produces an increase in plasma concentrations after acute administration 293 
(Babalonis et al., 2017; Englund et al., 2013), is well tolerated in humans (Grotenhermen et al., 294 
2017), produces a significant anxiolytic effect (Bergamaschiet al., 2011), produces opposing 295 
effects to THC on the striatum as assessed by fMRI (Bhattacharyya et al., 2010), and elicits 296 
anti-psychotic like effects in combination with THC (Bhattacharyya et al., 2015).  297 
 298 
Procedure 299 
Participants completed a screening on the telephone during which initial eligibility criteria 300 
(drug use, FTND, AUDIT, MRI contraindications, allergies, medical information, and 301 
handedness) were assessed and basic participant details were recorded. Participants that 302 
appeared eligible on the phone were invited to attend experimental sessions. Participants were 303 
asked to fast from midnight the day before both sessions, and refrain from smoking tobacco 304 
and consuming alcohol for 24 hours before the start of the sessions. Upon arrival, participants 305 
underwent urine tests to verify they were not pregnant (if female) and they had not recently 306 
taken recreational drugs. They also completed breath tests for alcohol and carbon monoxide.  307 
 308 
Eligible participants then completed two seven-hour experimental sessions, when they received 309 
CBD or PBO on the first session, and the other drug condition on the second session. 310 
Experimental sessions were separated by a minimum seven-day wash-out period (>4 times the 311 
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elimination half-life) to minimize carryover effects of CBD (Consroe et al., 1991). The BDI 312 
and WTAR were completed immediately after drug administration on the second session. 313 
Previous research suggests that CBD reaches the peak level of plasma concentration after 314 
approximately 2.5 hours (Babalonis et al., 2017). Therefore, 2.5 hours after drug 315 
administration, participants underwent MRI scanning for 1.5 hours to complete the MID task, 316 
as well as other tasks and scans, which will be reported elsewhere. Participants’ blood samples 317 
were taken straight after the scan finished, which was approximately 4 hours and 15 minutes 318 
after drug administration. After a standardised lunch provided by the experimenter, participants 319 
completed a series of questionnaires and computer tasks, results of which will be reported 320 
elsewhere. 321 
 322 
Power calculation 323 
A power calculation was conducted using G*Power (version 3.1.9.2). This showed that a 324 
sample size of 20 would have 81% power to detect a significant (p<0.05, two-tailed) difference 325 
between CBD and placebo (PBO) with a moderate or greater effect size of d=0.5. This effect 326 
size was based on the previous finding of the difference in the attentional bias toward cigarette 327 
cues between 800mg CBD vs. placebo in nicotine-dependent users (Hindocha et al., 2018). We 328 
then recruited extra participants to account for expected participant dropout and exclusions. 329 
 330 
MRI data acquisition  331 
MRI data was collected using a 3-Tesla Siemens Verio MRI Scanner at the Robert Steiner MR 332 
unit at Hammersmith Hospital, London. Functional imaging used a multiband (acceleration 333 
factor = 2) gradient-echo T2*-weighted echo-planar imaging (EPI) sequence with 42 slices per 334 
volume (TR = 2400ms; TE = 30ms; in-plane matrix = 64 x 64; 3mm isotropic voxels; flip angle 335 
= 62°; bandwidth = 1594 Hz/pixel; 304 volumes; a slice thickness of 3mm; field of view = 336 
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192mm x 192mm). The phase encoding direction was from anterior to posterior. Echo spacing 337 
was 0.71ms. There were 3 dummy scans at the beginning of the scan, which were not included 338 
in in our dataset. For structural acquisition, a T1-weighted structural volume was acquired for 339 
all participants using a Magnetisation Prepared Rapid Gradient Echo (MPRAGE) scan (TR = 340 
2300ms; TE = 2.28ms, TI= 900ms, flip angle = 9°, field of view= 256mm, image matrix = 256 341 
with 1-mm isotropic voxels; bandwidth = 200 Hz/pixel). 342 
 343 
Functional magnetic resonance imaging (fMRI) data analyses 344 
Image pre-processing and analysis were performed using FSL’s fMRI Expert Analysis Tool 345 
(FEAT) (FMRIB Software Library v6.0, Analysis Group, FMRIB, Oxford, UK) (Jenkinson et 346 
al., 2012). Data were pre-processed before being subject to first and second-level analyses. 347 
 348 
Pre-processing  349 
FSL’s brain extraction tool (BET) was used to strip the brain from the skull. FMRIB Automated 350 
Segmentation Tool was used to separate out grey matter, white matter, and cerebrospinal fluid. 351 
Functional images were realigned to the middle volume using FSL’s MCFLIRT procedure, in 352 
order to correct for head motion. Subsequently, the functional images were co-registered to the 353 
individual participant’s structural image and normalised to the MNI-152 (Montreal 354 
Neurological Institute) template using FEAT’s non-linear transformation procedure with a 355 
10mm warp resolution. An isotropic 6mm full-width at half-maximum Guassian kernel (i.e. 356 
twice the voxel size) was then applied to spatially smooth images. A high-pass filter (100s cut-357 
off) was applied to remove low-frequency noise. Images were visually inspected to ensure that 358 
the pre-processing had worked correctly. 359 
 360 
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T1-weighted structural images were also skull-stripped with FSL’s BET and normalised to the 361 
MNI-152 template. 362 
 363 
First level analyses 364 
Timestamps and durations for each event (cue, anticipate, target, feedback, inter-trial-interval) 365 
in the MID task were extracted from the task output files using scripts written in Matlab 366 
(Mathworks Inc., United States). A general linear model was created with the following 367 
explanatory variables (i.e. regressors): (1) reward anticipation (i.e. anticipate-win), (2) no 368 
reward anticipation (i.e. anticipate-neutral), (3) reward feedback on a successful win trial (i.e. 369 
feedback-win-hit), (4) no reward feedback on an unsuccessful win trial (i.e. feedback-win-370 
miss), (5) no reward feedback on a successful neutral trial (i.e. feedback-neutral-hit), (6) no 371 
reward feedback on an unsuccessful neutral trial (i.e. feedback-neutral-miss). Each event was 372 
modelled with a boxcar function with the event’s duration convolved with the canonical 373 
haemodynamic response function, using the gamma function. Extended motion parameters and 374 
temporal derivatives were included as additional regressors-of-no-interest. 375 
 376 
These contrasts were then calculated: 377 
(1) ‘reward anticipation’: anticipate-win > anticipate-neutral. 378 
(2) ‘reward feedback’: feedback-win-hit > feedback-neutral-hit. 379 
 380 
Second level analyses 381 
Whole brain analysis 382 
The second-level fMRI data analysis was also performed with FSL’s FEAT pipeline (Jenkinson 383 
et al., 2012), using a random effects analysis with FMRIB’s Local Analysis of Mixed Effects 384 
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(FLAME). We analysed the two contrasts specified above at the second level. We used 385 
clusterwise correction, with a cluster-defining threshold of z=2.3 and an alpha value of 0.05. 386 
We conducted one-sample t-tests for both contrasts, collapsing across both drug conditions, to 387 
investigate the overall effect of the task (reward anticipation and reward feedback) on brain 388 
activity. Secondly, we conducted paired t-tests for both contrasts to investigate the differences, 389 
in both directions, between CBD and PBO. 390 
 391 
Region of interest (ROI) analyses 392 
ROIs were pre-specified based on a meta-analysis of MID fMRI results for significantly 393 
activated regions for reward anticipation and feedback (Knutson and Greer, 2008). There were 394 
eight ROIs for anticipation and seven ROIs for feedback, as shown in Table 1. The Talairach 395 
coordinates from Knutson and Greer (2008) were converted to MNI coordinates using the 396 
mni2tal MATLAB function created by the University of Cambridge Medical Research Council 397 
Cognition and Brain Sciences Unit (http://imaging.mrc-398 
cbu.cam.ac.uk/imaging/MniTalairach). We used these coordinates as the centres for our 399 
spherical ROIs, with radii of 5mm. The ROIs were created using FSLeyes and fslmaths 400 
functions. We then extracted average unstandardized beta values (with arbitrary units) from 401 
these regions for the two contrasts described above. 402 
 403 
We then ran one-sample t-tests (against a score of zero) to test whether the task elicited the 404 
expected anticipation and feedback activation in the hypothesised regions. Subsequently, we 405 
ran paired t-tests for an effect of drug (CBD vs. PBO) on the activation in these anticipation 406 
and feedback ROIs. We reduced the alpha value to 0.006 to account for the multiple tests (i.e. 407 
ROIs) within each contrast. 408 
 409 
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We examined the extracted beta values for normality by visually inspecting histograms of the 410 
data, checking for kurtosis and skewness values >1, using Kolmogrov-Smirnov tests and 411 
looking for outliers as shown by SPSS’s box and whisker plots. Across all regions, for both 412 
CBD and PBO and for both reward anticipation and feedback the data were normally 413 
distributed, so data were left unchanged.  414 
 415 
[Insert Table 1] 416 
 417 
In order to gain further support for either the null or alternative hypothesis for the effects of 418 
CBD on brain activity during reward anticipation and feedback, we also calculated scaled 419 
Jeffreys-Zellner-Siow (JZS) Bayes factors using an online calculator 420 
(http://pcl.missouri.edu/bayesfactor) (Buckingham et al., 2016; Lawn et al., 2018). We used a 421 
scaled-information prior of r = 1, which is the default value recommended (Rouder et al., 2009). 422 
For this analysis, a Bayes factor of >3 provides support for the null hypothesis (i.e. no 423 
difference in activation between CBD and placebo).  424 
 425 
We conducted Pearson correlations between participant CBD plasma levels and their extracted 426 
beta values for each anticipate and feedback ROI, when they were on the CBD condition. We 427 
reduced the alpha value to 0.006 to account for multiple tests (i.e. ROIs) within each contrast. 428 
 429 
Behavioural analyses 430 
We conducted a Wilcoxon signed-rank test on the plasma CBD levels for CBD compared with 431 
PBO. 432 
 433 
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We conducted 2x2 repeated-measures analyses of variance (ANOVAs) for reaction time (RT) 434 
and the proportion of hits, with within-subjects factors of drug (CBD, PBO) and trial-type (win, 435 
neutral).  436 
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Results 437 
Demographics 438 
Of the 23 participants included in the analysis, there were 12 women and 11 men, with mean 439 
age 23.74 years (SD=4.2, range: 19-36). Participants’ depression (BDI mean=2.2, SD=4.9, 440 
range: 0 to 11) and problematic alcohol use (AUDIT mean=2.2, SD=2.8, range: 0-7) levels 441 
were low. Participants had a mean WTAR raw score of 40.5 (SD=4.9, range: 33-49) and a 442 
mean BMI of 22.4 kg/m2 (SD=3.5, range: 17.6-35.4).  443 
 444 
Plasma CBD levels 445 
Plasma CBD levels were higher on CBD (median=6.01ng/ml, interquartile range=4.89) than 446 
PBO (median=0, interquartile range=0) (Z=3.296, p=0.001). 447 
 448 
MID behavioural results 449 
For RT, there were main effects of drug (F1, 22=6.286, p=0.020) and trial-type (F1, 22=15.841, 450 
p=0.001), but there was not a significant interaction. Participants were faster to respond on win 451 
trials (mean=0.241s, SD=0.023) compared to neutral trials (mean=0.247s, SD=0.024). 452 
Participants were faster, overall, to respond under PBO (mean=0.241s, SD=0.024) compared 453 
to CBD (mean=0.247s, SD=0.024). 454 
 455 
For proportion hit, there was a main effect of trial-type (F1, 22=43.776, p<0.001), but no main 456 
effect of drug or interaction. Participants were more likely to hit on a win trial (mean=0.612, 457 
SD=0.079) compared to a neutral trial (mean=0.437, SD=0.072). 458 
 459 
  460 
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MID fMRI results 461 
Movement did not exceed 3mm (our voxel size) in any direction for any of the participants. 462 
Mean and maximum movements were: x: mean=0.15mm (SD=0.50mm), max=0.50mm; y: 463 
mean=0.19mm (SD=0.12), max=0.50mm; z: mean=0.34mm (SD=0.32mm), max=2.00. 464 
Therefore we did not exclude any participants for excess movement. 465 
 466 
Whole brain analyses 467 
Effects of task (Table 2, Figure 2, Figure 3) 468 
For the reward anticipation contrast, there was activation in three clusters, with peak activations 469 
in the insula bilaterally and the right paracingulate gyrus (Table 2). The right and left insula 470 
clusters extended into the right and left frontal operculum cortex, inferior frontal gyrus and 471 
orbitofrontal cortex. The paracingulate gyrus extended into the anterior cingulate gyrus, 472 
supplementary motor cortex and superior frontal gyrus (Figure 2). 473 
 474 
For the reward feedback contrast, there was very widespread activation in two large clusters: 475 
one more posterior and one more anterior (Table 2; Figure 3). The posterior had a peak 476 
activation in the left occipital fusiform gyrus and extended into the bilateral cerebellum, 477 
intracalcarine gyrus, lingual gyrus, precuneus, inferior and middle temporal cortex, anterior 478 
and posterior lateral occipital gyrus, postcentral gyrus, posterior supramarginal gyrus, and 479 
hippocampus, amongst others. The anterior cluster had a peak activation in the left precentral 480 
gyrus and extended into the bilateral anterior cingulate cortex, paracingulate gyrus, superior 481 
and middle frontal gyrus, frontal pole, precentral gyrus, frontal medial cortex, and frontal 482 
operculum, amongst others. Activity was also observed in bilateral caudate, accumbens, 483 
thalamus and pallidum. 484 
 485 
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[Insert Table 2] 486 
[Insert Figure 2] 487 
[Insert Figure 3] 488 
 489 
Effects of the drug 490 
No significant clusters were found for CBD>PBO or PBO>CBD for either reward anticipation 491 
or feedback. 492 
 493 
ROI analyses 494 
Effects of task (Table 3) 495 
For reward anticipation, only the right insula was significantly activated (t22=3.87, p=0.001) 496 
during reward anticipation. 497 
 498 
For reward feedback, the left (t22=3.31, p=0.003) and right (t22=3.38, p=0.003) 499 
parahippocampal gyri, right caudate (t22=3.46, p=0.002) and left nucleus accumbens (t22=4.02, 500 
p=0.001) were significantly activated during reward feedback. 501 
 502 
[Insert Table 3] 503 
 504 
Effects of drug (Table 4) 505 
CBD did not differ from PBO in all of the ROIs during reward anticipation (ps>0.1). 506 
Furthermore, all but one of the ROIs had a Bayes factor>3, in favour of there being no 507 
difference between drug conditions. 508 
 509 
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CBD did not differ from PBO in all of the ROIs during reward feedback (ps>0.3). Furthermore, 510 
all the ROIs had Bayes factors>3, in favour of there being no difference between drug 511 
conditions. 512 
 513 
[Insert Table 4] 514 
 515 
Correlations 516 
There were no significant correlations between plasma CBD levels and activation in any of the 517 
ROIs during anticipation or feedback. 518 
 519 
  520 
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Discussion 521 
We hypothesised that brain activity would be greater during reward anticipation and feedback 522 
following 600mg of oral CBD compared to PBO. However, this was not the case.  We found 523 
no evidence that CBD affects the brain’s response to reward anticipation or feedback. 524 
Furthermore, in pre-specified reward-related brain regions (Knutson and Greer, 2008), using 525 
Bayesian analyses, we found support for there being no difference in neural activity between 526 
CBD and PBO. Overall, we found no support for CBD affecting the neural correlates of reward 527 
anticipation and feedback or behavioural measures of motivation for reward in healthy 528 
volunteers. 529 
 530 
Across both drug conditions, in the whole brain, our MID task elicited reward anticipation 531 
activation in the bilateral insula and paracingulate gyrus, extending into inferior frontal gyri 532 
and orbitofrontal cortex. In our ROI analysis, the right insula was significantly activated during 533 
reward anticipation. Reward feedback elicited extensive activity across anterior and posterior 534 
parts of the brain, including a range of reward-related brain regions. In our ROI analysis, the 535 
right caudate, left nucleus accumbens and bilateral parahippocampal gyri were activated during 536 
reward feedback. These analyses demonstrate that anticipation and feedback of reward 537 
produced activity in several expected brain regions. Further support that the task functioned 538 
adequately is that both reaction time and hit rate were significantly affected by trial type, such 539 
that participants were faster and more likely to successfully hit the target on win trials compared 540 
to neutral trials. Importantly, our plasma results demonstrate that the 600mg oral dose of CBD 541 
was absorbed. 542 
 543 
In terms of behavioural outcomes, CBD led to longer reaction times compared to PBO overall. 544 
However, there was no interaction between drug and trial-type; CBD did not reduce reaction 545 
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times more for win trials than it did for neutral trials. Hence CBD did not affect our behavioural 546 
measure of motivation for reward; it simply increased reaction time, in general (i.e. comparably 547 
for both trial-types). This is somewhat surprising given previous research has not found CBD 548 
to affect reaction speed in general (Belgrave et al., 1979; Fusar-Poli et al., 2009; Hindocha et 549 
al., 2018). 550 
 551 
Despite some existing evidence that CBD can impact reward function, we found null results 552 
for its effects on the neural correlates of reward anticipation and feedback. This absence of 553 
impact on reward circuitry, may contribute to the lack of reinforcing and abuse potential of 554 
CBD (Haney et al., 2016). To our knowledge, no previous study has examined the effects of 555 
CBD alone on brain activity associated with reward processing or motivation for reward. 556 
Previous studies have often investigated how inhaled CBD moderates THC’s effects (Freeman 557 
et al., 2018; Lawn et al., 2016), which may have contributed to the discrepancy. Moreover, 558 
other studies have explored more complex components of reward function, including 559 
attentional bias toward drug pictures (Hindocha et al., 2018; Morgan et al., 2010). Other 560 
components of reward processing, including reward learning and subjective pleasure could also 561 
still be sensitive to a 600mg dose of oral CBD. CBD’s acute effects on human behaviour and 562 
subjective experience are seemingly complicated and enigmatic (Bergamaschi et al., 2011; 563 
Fusar-Poli et al., 2009; Haney et al., 2016; Morgan et al., 2010). The same may well be true 564 
with regards to CBD’s impacts on reward processing. 565 
 566 
Furthermore, long-term daily administration of CBD, as delivered in clinical trials (Freeman et 567 
al., in press; Leweke et al., 2012; McGuire et al., 2018), could produce different effects on the 568 
neural correlates of reward anticipation and feedback. We only delivered a single oral 600mg 569 
dose in healthy volunteers. CBD likely has complex, variable dose-response functions on 570 
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diverse psychological outcomes (Zuardi et al., 2017). Nevertheless, experimental medicine 571 
approaches, such as this one, are needed to efficiently examine the acute effects of potentially 572 
therapeutic drugs in human models of psychiatric targets, where clinical trials are costly and 573 
protracted.  Future research into CBD’s effects on reward processing should expand the reward 574 
components assessed and utilise different doses. It should also examine consequences of 575 
repeated, long-term administration, which may allow for CBD levels to build up in the body 576 
and have greater impacts on receptor expression and endocannabinoid levels. 577 
 578 
The present results leave open the intriguing possibility that CBD may only exert an effect on 579 
reward networks that have already been perturbed, for example in people with a drug addiction. 580 
CBD administration has been shown to modulate reward-related behaviours in animals when 581 
addiction is being modelled (Katsidoni et al., 2013; Parker et al., 2004; Ren et al., 2009; Schier 582 
et al., 2014; Viudez-Martínez et al., 2018). Moreover, behavioural evidence from human 583 
studies suggests that CBD can reduce the salience of drug-related cues in those with cannabis 584 
(Morgan et al., 2010) and nicotine (Hindocha et al., 2018) dependencies, and reduce drug cue-585 
induced cravings in those addicted to heroin (Hurd et al., 2019). Additionally, a four-week 586 
treatment of CBD dose-dependently decreased cannabis use in a clinical trial of people with 587 
cannabis use disorder (Freeman et al., in press). In all of these studies, CBD attenuated atypical 588 
reward-related behaviours conferred by addiction, suggesting a restorative effect. Therefore, 589 
the null findings reported in the present study could have resulted from our sample of healthy 590 
volunteers. Future neuroimaging research should therefore administer CBD to participants 591 
thought to have perturbed reward systems, including those with addiction.  592 
 593 
The reward system is thought to be critically involved in the emergence and/or maintenance of 594 
a variety of psychiatric disorders, including depression (Nestler and Carlezon, 2006; Whitton 595 
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et al., 2016), schizophrenia (Kapur et al., 2005; Whitton et al., 2016) and addiction (Berridge 596 
and Robinson, 2016; Goldstein and Volkow, 2011). If it emerges that CBD does have accepted 597 
therapeutic effects in these domains, further research will be needed to understand whether or 598 
not the mechanism is related to reward circuitry. Moreover, an improved understanding of 599 
CBD’s pharmacological actions and their relative importance in treating reward-related 600 
psychological symptoms will be important in the development of cannabinoid-based 601 
psychiatric medicines. One possible avenue for future research would be to further understand 602 
and capitalize on CBD’s agonism of the serotonin-1a receptor (Russo et al., 2005), in order to 603 
potentially disrupt addition and depressive symptoms. 604 
 605 
Strengths and Limitations 606 
Our study has a number of strengths. First and foremost, it was a double-blind, placebo-607 
controlled experiment addressing a novel and important research question. Second, we utilised 608 
a well-validated fMRI task which elicited activity in many expected brain regions and 609 
appropriately affected behavioural performance. Third, CBD was absorbed into the 610 
bloodstream. Fourth, we conducted Bayesian analyses to provide support for null findings. 611 
 612 
However, there are some limitations. Despite stimulating activity in many expected brain 613 
regions, the MID failed to produce anticipatory activation in the striatum, which is the region 614 
most commonly found to respond in this stage of the task (Oldham et al., 2018). Thus, CBD 615 
could theoretically affect striatal activity (Bhattacharyya et al., 2010) and we may have failed 616 
to detect it here. Finally, although CBD was absorbed relative to placebo, our plasma levels 617 
were lower than that seen in previous oral CBD studies (Haney et al., 2016; Millar et al., 2018). 618 
This may have been caused by our fasting participants, as a large, high-fat meal eaten before 619 
CBD administration can augment bioavailability four-fold (Taylor et al., 2018). Therefore, we 620 
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cannot exclude the possibility that if greater quantities of CBD had been absorbed, we may 621 
have observed different results. We also do not know whether 600mg is the optimal dose to 622 
manipulate reward processing, especially given CBD’s potentially inverted U-shaped dose-623 
response curve (Zuardi et al., 2017). Additionally, we did not control or account for female 624 
participants being in different stages of their menstrual cycle, which can affect 625 
psychopharmacological phenomena (Bolea-Alamanac et al., 2018). 626 
 627 
Conclusion 628 
To conclude, in healthy volunteers, a single, oral 600mg dose of CBD did not affect the neural 629 
correlates of reward anticipation and feedback, or behavioural measures of motivation for 630 
reward.  631 
632 
 30 
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